Ripk2 dictates blood insulin and glucose responses to cancer drug and microbial xenobiotics

Xenobiotics, including therapeutic drugs, and components of microbes can promote inflammation that contributes to insulin resistance and dysglycemia. Tyrosine kinase inhibitors (TKIs) used in cancer have been considered as a therapy in diabetes and its complications. It is not clear which molecular target of TKIs impact blood glucose or insulin during obesity. One objective here was to define the role of the innate immune adapter protein, Ripk2 …